Have not posted for a while and thought this publication would be of interest to the community. (This article belongs to the Special Issue Maximising Drug Delivery for Improved Pharmacokinetics and Pharmacodynamics)
Early Stage Preclinical Formulation Strategies to Alter the Pharmacokinetic Profile of Two Small Molecule Therapeutics. Le An et al.
Pharmaceuticals 2024, 17(2), 179;
Early Stage Preclinical Formulation Strategies to Alter the Pharmacokinetic Profile of Two Small Molecule Therapeutics
| MDPI |
remove preview |
|
| Early Stage Preclinical Formulation Strategies to Alter the Pharmacokinetic Profile of Two Small Molecule Therapeutics |
| Early stage chemical development presents numerous challenges, and achieving a functional balance is a major hurdle, with many early compounds not meeting the clinical requirements for advancement benchmarks due to issues like poor oral bioavailability. There is a need to develop strategies for achieving the desired systemic concentration for these compounds. |
| View this on MDPI > |
|
|
Keywords: drug delivery; PO; IV infusion; IP; SC; small molecule; PK profile; exposure
------------------------------
Tsung Tan
Drug Delivery and Infusion Department Manager
Primetech Corporation
Tokyo
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------